Celldex Therapeutics (CLDX) News Today $22.19 +0.21 (+0.96%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$22.00 -0.19 (-0.86%) As of 08/1/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Celldex Therapeutics’ Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic UrticariaAugust 1 at 12:41 PM | tipranks.comGSA Capital Partners LLP Makes New Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)July 31 at 3:22 AM | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 16, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Share Price Passes Above 200-Day Moving Average - Should You Sell?July 4, 2025 | marketbeat.comCLDX Celldex Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 21, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Shares Down 5.5% - Should You Sell?June 16, 2025 | marketbeat.comCelldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025June 16, 2025 | morningstar.comMQ2 Earnings Estimate for CLDX Issued By Lifesci CapitalJune 16, 2025 | marketbeat.comCelldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challengesJune 15, 2025 | investing.comCelldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025June 14, 2025 | globenewswire.comCelldex shares jump on impressive skin disorder drug dataJune 13, 2025 | in.investing.comCelldex Therapeutics (NASDAQ:CLDX) Trading Up 9% - Here's WhyJune 13, 2025 | marketbeat.comForecasting The Future: 8 Analyst Projections For Celldex TherapeuticsJune 13, 2025 | benzinga.comCelldex Therapeutics' (CLDX) Buy Rating Reaffirmed at HC WainwrightJune 13, 2025 | marketbeat.comCelldex Therapeutics Inc (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in Chronic ...June 12, 2025 | gurufocus.comCelldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025June 12, 2025 | globenewswire.comCelldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 CongressJune 10, 2025 | globenewswire.comEquities Analysts Issue Forecasts for CLDX FY2026 EarningsJune 10, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Trading Down 4.5% - Should You Sell?June 9, 2025 | marketbeat.comTwo Sigma Investments LP Buys Shares of 33,025 Celldex Therapeutics, Inc. (NASDAQ:CLDX)June 7, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Bank of America Corp DEJune 7, 2025 | marketbeat.comCelldex Approves Equity Plan Amendment and Elects New DirectorJune 6, 2025 | tipranks.comCelldex Therapeutics Announces Election of Denice Torres to its Board of DirectorsJune 6, 2025 | globenewswire.comApella Capital LLC Invests $309,000 in Celldex Therapeutics, Inc. (NASDAQ:CLDX)June 6, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)June 6, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume - Here's WhyJune 4, 2025 | marketbeat.comMillennium Management LLC Has $2.37 Million Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)June 2, 2025 | marketbeat.comNuveen Asset Management LLC Sells 75,257 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 31, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Stock Price Up 6.6% - Time to Buy?May 30, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Stock Price Down 3.5% - Should You Sell?May 29, 2025 | marketbeat.comPolar Asset Management Partners Inc. Grows Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 28, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of "Moderate Buy" by AnalystsMay 28, 2025 | marketbeat.comTFG Asset Management GP Ltd Invests $4.85 Million in Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 27, 2025 | marketbeat.comCelldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growthMay 24, 2025 | investing.comTwinbeech Capital LP Reduces Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 24, 2025 | marketbeat.comDeutsche Bank AG Acquires 82,042 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 23, 2025 | marketbeat.comWoodline Partners LP Cuts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 22, 2025 | marketbeat.comVestal Point Capital LP Acquires Shares of 305,000 Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 21, 2025 | marketbeat.comRafferty Asset Management LLC Acquires 61,464 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 21, 2025 | marketbeat.comBNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 21, 2025 | marketbeat.com29,480 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by Tema Etfs LLCMay 20, 2025 | marketbeat.com192,000 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by TFG Asset Management GP LtdMay 20, 2025 | marketbeat.comSphera Funds Management LTD. Has $11.98 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 18, 2025 | marketbeat.comPoint72 Asset Management L.P. Acquires 847,264 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 18, 2025 | marketbeat.comPolar Asset Management Partners Inc. Grows Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 18, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 18, 2025 | marketbeat.comPolar Capital Holdings Plc Cuts Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 17, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 306,777 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)May 16, 2025 | marketbeat.comLeerink Partnrs Issues Pessimistic Outlook for CLDX EarningsMay 14, 2025 | marketbeat.com Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Media Mentions By Week CLDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼1.630.63▲Average Medical News Sentiment CLDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼25▲CLDX Articles Average Week Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alkermes News Ligand Pharmaceuticals News Amicus Therapeutics News BioCryst Pharmaceuticals News Dynavax Technologies News MannKind News Novavax News Innoviva News OPKO Health News Geron News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
